Based in New York, United States, Pfizer is a Pharmaceutical manufacturing company established in 1849 (NYSE: PFE).
Pfizer Inc. is a biopharmaceutical company with global headquarters at 66 Hudson Boulevard East in New York City. Cousins Charles Pfizer and Charles Erhart founded Charles Pfizer & Company in 1849 in a red brick building in Brooklyn, and the present company was incorporated in Delaware on June 2, 1942. Its common stock trades on the New York Stock Exchange under the ticker PFE. Pfizer discovers, develops, manufactures and sells medicines and vaccines across oncology, internal medicine, inflammation and immunology, and vaccines, and manages its commercial operations through three operating segments: Biopharma, PC1 and Pfizer Ignite. It reported revenues of 62.6 billion dollars for 2025 and employed approximately 75,000 people worldwide at year end. Pfizer Global Supply runs 36 manufacturing plants, including in Belgium, Germany, India, Ireland, Italy, Japan, Singapore and the United States. Albert Bourla has been chief executive officer since January 2019 and chairman since January 2020. The company acquired Seagen in December 2023 and Metsera in November 2025. It employs Approximately 75,000 people worldwide (Form 10-K, December 31, 2025) people, led by Albert Bourla (Chairman and Chief Executive Officer), across roughly 75,000 tracked profiles. Firmographics, leadership, tech stack and similar companies are detailed below, as of 2026-11-12.
Get this data with Derrick Enrich Companies
Pfizer tech stack
52 technologies detected on pfizer.com, as of 2026-11-12.
| Name | Technologies | Share |
|---|---|---|
| JavaScript library | 3 | 5.8% |
| Programming language | 3 | 5.8% |
| Advertising | 2 | 3.8% |
| Analytics | 2 | 3.8% |
| Bot protection | 2 | 3.8% |
| CDN | 2 | 3.8% |
| Real user monitoring | 2 | 3.8% |
| Tag management | 2 | 3.8% |
| Technology | Category |
|---|---|
| D | CMS |
| H | Static site generator |
| Q | Investor relations platform |
| A | Analytics |
| A | Data management platform |
| A | Customer data platform |
| A | Tag management |
| G | Analytics |
| G | Tag management |
| M | Product analytics |
| S | Behavioral data platform |
| D | Digital experience analytics |
| M | Customer experience management |
| C | Real user monitoring |
| A | Real user monitoring |
| O | Application monitoring |
| F | Advertising |
| L | Advertising |
| A | Cloud hosting |
| A | Load balancer |
| A | CDN |
| A | Object storage |
| A | Email delivery |
| C | CDN |
| C | Bot protection |
| V | HTTP cache |
| A | Web server |
| I | Web server |
| W | Operating system |
| O | Application server |
| M | Web framework |
| J | Programming language |
| P | Programming language |
| T | Programming language |
| A | JavaScript framework |
| P | JavaScript library |
| l | Web components library |
| j | JavaScript library |
| B | UI framework |
| Z | UI framework |
| S | JavaScript library |
| V | Video player |
| Y | Video hosting |
| L | Animation |
| T | Web fonts |
| F | Icon library |
| O | Consent management |
| r | Bot protection |
| S | IT service management |
| D | E-signature |
| A | Social sharing |
| A |
Get this data with Derrick Website Technologies
Pfizer news & media
- PPfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program
Blackstone will be eligible for milestone payments tied to U.S. approval of monthly injectable berobenatide and to commercial sales milestones.
- PPfizer Appoints Cecile Guegan as Chief Financial Officer
The board appointed her unanimously; she brings more than 25 years of pharmaceutical finance experience.
- PPfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance
Third-quarter revenues came to 16.6 billion dollars, after 15.0 billion dollars in the second quarter and 14.5 billion dollars in the first.
- PPfizer's ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint in Phase 3 Study in Relapsed or Refractory Multiple Myeloma
More than 75% of patients on ELREXFIO had not progressed or died at the time of the analysis, with an estimated 68% progression-free survival at 18 months.
- PPfizer's TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting
TALAPRO-3 showed an estimated 52% reduction in the risk of radiographic progression or death.
- PPfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026
A four-dose series produced immune responses against all 25 serotypes, with safety comparable to PREVNAR 20.
- PPfizer's TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
The regimen showed more than 50% improvement in median progression-free survival in HER2CLIMB-05.
- PPfizer Declares Fourth-Quarter 2026 Dividend
The 0.43 dollar dividend goes to holders of record at the close of business on November 6, 2026.
- PPfizer's LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo
Results from the TRANQUILLO and TRANQUILLO 2 Phase 3 trials were presented at the EADV congress in Vienna.
- PPfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
The trispecific antibody binds IL-4, IL-13 and TSLP and has a half-life of about 37 days, which could support monthly dosing.
- PPfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
The approval covers adults 65 and older and people aged 5 through 64 with at least one underlying high-risk condition.
- PPfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
The 6-valent OspA-based candidate was well tolerated in the VALOR trial, in people aged five and older.
- PPfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
Second-quarter revenues were 15.0 billion dollars, for 29.5 billion dollars over the first half of 2026.
- PU.S. FDA Approves PADCEV plus Keytruda as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
The approval, with Astellas, rests on Phase 3 EV-304 data showing a 35% reduction in the risk of death versus standard of care.
- PPfizer Announces Chief Financial Officer Transition
Dave Denton was to leave on August 15, with Cecile Guegan named interim chief financial officer from August 16.
Get this data with Derrick Google News Scraper
Pfizer recent signals
- Signed a co-funding agreement under which funds managed by Blackstone Life Sciences will pay up to 1.5 billion dollars of development costs through 2028 for berobenatide, an investigational monthly GLP-1 receptor agonist for chronic weight managementNovember 2026
- The board appointed Cecile Guegan chief financial officer and executive vice president, effective November 1, 2026; she had been interim chief financial officer since August 16, 2026November 2026
- Reported third-quarter 2026 revenues of 16.6 billion dollars, bringing revenues for the first nine months of 2026 to 46.1 billion dollars, and raised its 2026 guidanceNovember 2026
- The FDA expanded approval of TALZENNA plus XTANDI to an earlier metastatic prostate cancer setting for men with HRR gene mutations, based on Phase 3 TALAPRO-3 dataOctober 2026
- ELREXFIO met its primary endpoint of progression-free survival in the Phase 3 MagnetisMM-32 study in relapsed or refractory multiple myelomaOctober 2026
- The FDA approved TUKYSA with trastuzumab and pertuzumab as a chemotherapy-free front-line maintenance treatment for HER2-positive metastatic breast cancerOctober 2026
- Declared a fourth-quarter 2026 dividend of 0.43 dollars per share, payable December 7, 2026, the 352nd consecutive quarterly dividend paid by the companyOctober 2026
- The FDA approved the 2026-2027 COVID-19 vaccine formula from Pfizer and BioNTech targeting the XFG variant, with shipping starting immediatelyAugust 2026
- The European Medicines Agency validated the marketing authorization application for the Lyme disease vaccine candidate developed with Valneva, based on efficacy of more than 70% in the Phase 3 VALOR trialAugust 2026
- Chief financial officer Dave Denton left the company on August 15, 2026 for a role in consumer goodsAugust 2026
- Completed the acquisition of Metsera, the base of its obesity and cardiometabolic pipelineNovember 2025
Get this data with Derrick Signal
Pfizer workforce (~75,000 tracked)
Distribution estimated from roughly 75,000 tracked public profiles, as of 2026-11-12. Use it for proportions, not exact headcounts.
- United States30,00040%
- Europe22,00029%
- Asia Pacific14,00019%
- Latin America5,0006.7%
- Africa and Middle East4,0005.3%
| Name | Profiles | Share |
|---|---|---|
| United States | 30,000 | 40% |
| Europe | 22,000 | 29% |
| Asia Pacific | 14,000 | 19% |
| Latin America | 5,000 | 6.7% |
| Africa and Middle East | 4,000 | 5.3% |
| Name | Profiles | Share |
|---|---|---|
| Executive Leadership Team | 10 | <0.1% |
| Senior vice presidents and vice presidents | 900 | 1.2% |
| Directors and senior managers | 9,000 | 12% |
| Managers and team leads | 16,000 | 21% |
| Individual contributors | 49,090 | 65% |
Get this data with Derrick Find a company's people
Pfizer leadership
10 current leaders are tracked, led by Albert Bourla. Contact details stay locked on this page and are revealed in the app.
| Leader | Profile | |
|---|---|---|
AB Albert BourlaChairman and Chief Executive Officer | ••••@pfizer.com | Profile → |
| CGCecile GueganChief Financial Officer and Executive Vice President | ••••@pfizer.com | Profile → |
| CBChris BoshoffChief Scientific Officer and President, Research & Development | ••••@pfizer.com | Profile → |
| AMAamir MalikChief U.S. Commercial Officer | ••••@pfizer.com | Profile → |
| ADAlexandre de GermayChief International Commercial Officer | ••••@pfizer.com | Profile → |
| DLDoug LanklerChief Legal Officer | ••••@pfizer.com | Profile → |
| MMMike McDermottChief Global Supply and Quality Officer | ••••@pfizer.com | Profile → |
| PSPayal SahniChief People Experience Officer | ••••@pfizer.com | Profile → |
| DHDennis HancockChief Information Officer | ••••@pfizer.com | Profile → |
| LHLindsay HavernHead of Strategy, Executive Operations, Counsel to the CEO | ••••@pfizer.com | Profile → |
Get this data with Derrick Find a company's people
Find verified emails for the 10 leaders listed here and anyone else at Pfizer in the Derrick web app (5 credits per email found), or track Pfizer with Signal to be alerted when its leaders change jobs, it raises funds or starts hiring (Standard plan and up).
Companies similar to Pfizer
| Company | Revenue | Employees | HQ | Founded |
|---|---|---|---|---|
| M | United States | |||
| J | United States | |||
| A | United States | |||
| B | United States | |||
| E | United States | |||
| N | Switzerland | |||
| R | Switzerland | |||
| A | United Kingdom |
Get this data with Derrick Find Similar Companies
Pfizer org chart
Albert BourlaChairman and Chief Executive Officer- CGCecile GueganChief Financial Officer and Executive Vice President
- CBChris BoshoffChief Scientific Officer and President, Research & Development
- AMAamir MalikChief U.S. Commercial Officer
- ADAlexandre de GermayChief International Commercial Officer
- DLDoug LanklerChief Legal Officer
- MMMike McDermottChief Global Supply and Quality Officer
- PSPayal SahniChief People Experience Officer
- DHDennis HancockChief Information Officer
- LHLindsay HavernHead of Strategy, Executive Operations, Counsel to the CEO
Get this data with Derrick Find a company's people